The study reports real world data in type 2 and 3 SMA patients treated for at least 2 years with nusinersen. Increase in motor function was observed after 12 months and during the second year. The magnitude of change was variable across age and functional subgroup, with the largest changes observed in young patients with higher function at baseline. When compared to natural history data, the difference between study cohort and untreated patients swas significant on both Hammersmith Functional Motor Scale and Revised Upper Limb Module both at 12 months and at 24 months.

Pane, M., Coratti, G., Pera, M. C., Sansone, V. A., Messina, S., D'Amico, A., Bruno, C., Salmin, F., Albamonte, E., De Sanctis, R., Sframeli, M., Di Bella, V., Morando, S., Palermo, C., Frongia, A. L., Antonaci, L., Capasso, A., Catteruccia, M., Longo, A., Ricci, M., Cutrona, C., Pirola, A., Bravetti, C., Pedemonte, M., Brolatti, N., Bertini, E. S., Mercuri, E. M., Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy, <<ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY>>, 2022; 9 (3): 404-409. [doi:10.1002/acn3.51514] [http://hdl.handle.net/10807/197785]

Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy

Pane, Marika;Coratti, Giorgia;Pera, Maria Carmela;D'Amico, Adele;De Sanctis, Roberto;Frongia, Anna Lia;Antonaci, Laura;Capasso, Anna;Longo, Antonella;Ricci, Martina;Cutrona, Costanza;Bertini, Enrico Silvio;Mercuri, Eugenio Maria
2022

Abstract

The study reports real world data in type 2 and 3 SMA patients treated for at least 2 years with nusinersen. Increase in motor function was observed after 12 months and during the second year. The magnitude of change was variable across age and functional subgroup, with the largest changes observed in young patients with higher function at baseline. When compared to natural history data, the difference between study cohort and untreated patients swas significant on both Hammersmith Functional Motor Scale and Revised Upper Limb Module both at 12 months and at 24 months.
2022
Inglese
Pane, M., Coratti, G., Pera, M. C., Sansone, V. A., Messina, S., D'Amico, A., Bruno, C., Salmin, F., Albamonte, E., De Sanctis, R., Sframeli, M., Di Bella, V., Morando, S., Palermo, C., Frongia, A. L., Antonaci, L., Capasso, A., Catteruccia, M., Longo, A., Ricci, M., Cutrona, C., Pirola, A., Bravetti, C., Pedemonte, M., Brolatti, N., Bertini, E. S., Mercuri, E. M., Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy, <<ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY>>, 2022; 9 (3): 404-409. [doi:10.1002/acn3.51514] [http://hdl.handle.net/10807/197785]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/197785
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 16
social impact